PRICED Act

Summary

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period. This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 23 June 2016

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 23 June 2016

   Introduced

   Introduced in House

   Source: IntroReferral

3. 23 June 2016

   Introduced

   Introduced in House

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 23 June 2016 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 23 June 2016

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 23 June 2016

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 23 June 2016

  Open at official source

Sponsors

• Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
• ELIJAH CUMMINGS · D · Sponsor
• Rep. McDermott, Jim [D-WA-7] · D · Sponsor
• Rep. Doggett, Lloyd [D-TX-37] · D · Sponsor
• Sen. Welch, Peter [D-VT] · D · Sponsor
• Marcy Kaptur · D · Cosponsor
• Rosa DeLauro · D · Cosponsor
• Ann Kirkpatrick · D · Cosponsor
• Timothy Walz · D · Cosponsor
• · hsif00 · Standing

Related records

• related to → PRICED Act
• related to ← PRICED Act